We compared a multiplex viral transplant panel on the ICEPlex system to real-time PCR for the detection of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK virus (BKV). The sensitivities of the ICEPlex were 83.3%, 95.5%, and 65.5% for the detection of CMV, EBV, and BKV, respectively. Interestingly, the multiplex assay detected dual infections in 16/280 (5.7%) samples tested.
V iral infections may result in nonspecific clinical manifestations in transplant patients, and therefore, health care providers often rely on laboratory testing to identify the etiologic agent. Nonmolecular methods, such as culture and histopathology, have important limitations, including prolonged turnaround time, manual processing and interpretation, and lack of sensitivity and specificity (1) . In recent years, molecular methods have been developed to reduce turnaround time and to increase sensitivity; however, most molecular assays are designed to detect a single analyte per reaction due to the inherent decrease in sensitivity that occurs when using multiplex real-time PCR assays (2) (3) (4) . In this study, we evaluated a multiplex viral panel for Epstein-Barr virus (EBV), cytomegalovirus (CMV), BK virus (BKV), human herpesvirus 6 (HHV-6), and HHV-7 using the ICEPlex system (PrimeraDx, Mansfield, MA). We compared the performance of this assay to that of uniplex real-time PCR. The ICEPlex platform utilizes routine PCR, in which amplicons are labeled with fluorescent dyes. Subsequently, amplicons are detected and separated by size using integrated capillary electrophoresis in real time (5) . The separation of PCR products based on size instead of probe-based chemistry may help minimize the loss in sensitivity that commonly occurs with multiplex assays.
For this study, prospective clinical samples (n ϭ 280) were submitted to our reference laboratory for routine real-time PCR for BKV (n ϭ 56 EDTA plasma samples and 56 urine samples), CMV (n ϭ 56 EDTA plasma samples), or EBV (n ϭ 112 wholeblood samples). In brief, nucleic acid from 200 l of each specimen was extracted into 100 l of elution buffer using the MagNA Pure (Roche Diagnostics, Indianapolis, IN) total nucleic acid program. Routine quantitative CMV and EBV testing was performed using analyte-specific reagents (ASR) (Roche Diagnostics, Indianapolis, IN), while BKV real-time PCR was performed using a laboratory-developed test (LDT) targeting the large T antigen. For BKV, the forward and reverse primer sequences were 5=-TGAAA GCCTTTACACAAATGTAAC-3= and 5=-ATTCTTGATATTACA AGAGAAGAAGAT-3=, respectively. Fluorescent resonance energy transfer (FRET) probe sequences were tagged with fluorescein (FL) or Red 640 (R640) (GGGAAGAGCATTGTGATTGGGA T-FL and R640-AGTGCTTGATCCATGTCCAGAGTCTT-phosphate). Qualitative HHV-6 and HHV-7 real-time PCR was performed using the LDT whenever a sample was determined by the ICEPlex system to be positive for these viruses. For HHV-6, the forward and reverse primer sequences were TGATCTACTTTC TGACTCACTCAACACA and AATCCTGAGGCGGGCATATA AAT, respectively. The FRET probe sequences were CATAACGG CAGCGCAAAACTACATCCAG-FL and R640-ACACACT TCTGAAACAGTGGGCGGTCTT-phosphate. For HHV-7, the forward and reverse primer sequences were TGTTTTTCACAGG AGATATTCT and CTTGACACCAACATCTGTCT, respectively. The FRET probe sequences were TACAGTGTACGCACCACAT AATTTAC-FL and R640-TTTCTATCCCAGCTGTTTTCATAT AG-phosphate. For each of the real-time PCR assays, 5 l of nucleic acid was combined with 15 l of master mix (CMV/EBV [Roche ASR]; BKV [primers/probes, TIB Molbiol [Adelphia, NJ]) and tested using the LightCycler 2.0 (Roche). The cycling conditions were 1 cycle at 95°C for 10 min; 45 cycles at 95°C for 10 s, 55°C for 15 s, and 72°C for 15 s; 1 cycle of continuous acquisition at 95°C with no hold, followed by 59°C for 20 s, 40°C for 20 s, and 85°C with no hold; and 1 cycle at 40°C for 30 s.
In addition to the routine testing described above, each sample was tested in a blinded fashion by a prototype viral transplant panel (PrimeraDx) using the ICEPlex system. The multiplex panel is designed to target CMV, EBV, BKV, HHV-6, and HHV-7. Testing by the ICEPlex was performed according to the manufacturer's recommended protocol. In brief, 35 l of PCR master mix (consisting of 25 l of Qiagen buffer, 2 l of primer mix, 0.5 l of universal assay reagent, 2 l of sensitivity controls, 1 l of HotStarTaq [Qiagen], and 4 l of water) was added to each well of a 96-well microtiter plate. The primers used for the detection of CMV, BKV, EBV, HHV-6, and HHV-7 were designed by PrimeraDx and were previously described (5) . From each extracted clinical sample, 15 l of nucleic acid was then added to each well. Up to 48 samples could be processed at one time, and blank wells were filled with 50 l of injection buffer (PrimeraDx). The plate was centrifuged briefly and then placed on the ICEPlex instrument for analysis according to the manufacturer's procedure. The use of all specimens in this study was reviewed and approved by the Mayo Clinic Institutional Review Board.
Following testing of 280 prospective clinical samples, the ICEPlex assay demonstrated an overall agreement among qualitative results of 93.2% (261/280) with real-time PCR (Table 1) Among the 280 samples tested in our study, there were 19 (6.8%) that showed discordant results between the ICEPlex and real-time PCR. However, further analysis of these samples showed that they contained analytes near the limit of detection (LoD) and below the limit of quantification. Although this study did not address the quantitative capabilities of the ICEPlex, LoD studies were carried out by spiking control material (AcroMetrix, Life Technologies, Grand Island, NY) into an analyte-negative sample matrix to create a 2-fold dilution panel (125,000 copies/ml to 244 copies/ml). Each dilution was then tested in triplicate by the ICEPlex and real-time PCR assays, with the LoD being defined as the highest dilution at which 3 out of 3 replicates were positive. The LoDs for CMV were 977 copies/ml by real-time PCR and 244 copies/ml by the ICEPlex. For EBV and BKV, the LoDs were determined to be 977 and 488 copies/ml, respectively, by both the ICEPlex and real-time PCR. We found it interesting that the observed BKV LoD (488 copies/ml) was the same with the ICEPlex and real-time PCR, but the overall agreement was poor ( ϭ 0.13) among clinical plasma samples. This may be due to differences in the actual LoD in clinical samples versus that in spiked samples or to the variability in detection when BKV is present at or near the LoD.
In 38 (13.6%) of 280 samples, the ICEPlex assay detected a target(s) that was not initially requested by the ordering provider (data not shown). Among these 38 samples, the results were confirmed in 34 samples (89.5%) using uniplex real-time PCR. Furthermore, the ICEPlex detected multiple viruses (Ն2) in 16 (5.7%) specimens, with the results from 15 (93.8%) of them being confirmed by individual real-time PCR (Table 2) . Interestingly, the majority (81.3%; 13/16) of coinfections were detected in whole-blood samples submitted for EBV PCR. The potential significance of detecting multiple viruses (e.g., EBV and HHV-7) in clinical samples will be an important area of future research.
This study had several limitations that should be discussed. First, samples were submitted to our reference laboratory for testing, and we were therefore not able to correlate the results with clinical findings or treatment decisions. Second, a thorough assessment of the quantitative capabilities of the ICEPlex could not be performed due to the low number of samples with positive results within the linear range of quantification. Further studies should be performed to better characterize the quantitative accuracy of the ICEPlex system. Specifically, it will be important to compare the ICEPlex to an FDA-approved viral load assay (e.g., Roche Cobas CMV) to determine if quantitative values correlate with results generated using the World Health Organization international standards (6) . Third, we should emphasize that the ICEPlex is considered an open molecular platform, which can be a potential source of amplicon contamination. To assess this possibility, an environmental screening of the laboratory work area (e.g., benchtop, instrumentation) and materials (e.g., pipettes) was performed at the completion of the study, and all environmental samples were negative. We also analyzed the potential for carryover contamination within the ICEPlex instrument by placing known positive and negative samples in alternate positions of a 96-well plate, and no carryover contamination was observed. However, the possibility of amplicon contamination remains an important consideration for clinical laboratories using open molecular platforms, and the appropriate sample workflow and contamination precautions must be followed. In summary, our evaluation showed good overall agreement ( ϭ 0.78) between the ICEPlex and routine real-time PCR for the detection of CMV, EBV, and BKV. However, we observed lower sensitivities with the ICEPlex BKV assay for urine (78.3%) and plasma (16.7%), suggesting that more data are needed prior to this assay being considered for routine testing. In addition, the quantitative capabilities of the ICEPlex deserves further characterization, as the qualitative detection of latent viruses, such as CMV and EBV, may not be sufficient in certain patient populations (e.g., transplant recipients). In these patients, there is an important balance between analytical sensitivity and clinical specificity, and monitoring the viral load over time can assist in diagnostic and treatment decisions.
